Rezolute combines a business quality score far below the required floor, a confirmed price downtrend, high short interest, and repeated earnings misses, consistent with the binary clinical-stage risk profile behind a call to exit the position.
Thesis pillars
- Quality Below Minimum Floor→Stable
- Confirmed Downtrend With Overbought Bounce↓Deteriorating
- High Short Interest And Binary Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Rezolute, Inc. (RZLT) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.87: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality.
Rezolute is a late-stage rare disease company focused on hypoglycemia caused by hyperinsulinism. Its lead clinical asset, ersodetug, is an intravenously administered antibody being studied for multiple forms of hyperinsulinism. It has no commercial revenue disclosed in Item 1.
Sell if holding. Engine safety override at $4.87: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 24d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Rezolute, Inc.
About Rezolute, Inc.
Rezolute is advancing ersodetug, its lead antibody candidate, through two pivotal Phase 3 trials for hyperinsulinism-driven hypoglycemia: sunRIZE, which completed enrollment of more than 56 participants across a dozen countries in May 2025, and upLIFT, a truncated single-arm study for tumor HI. The company incurred $61.5 million in research and development expense in fiscal 2025 and reported a $403.9 million accumulated deficit as of June 30, 2025, with no approved products generating revenue yet.
Rezolute holds a worldwide, exclusive license from XOMA covering the ersodetug molecule, including 38 issued patents that expire between 2030 and 2036, and relies on a small number of third-party suppliers for raw materials used in clinical and future commercial manufacturing. The company depends on outside contract research organizations to run its clinical trials rather than conducting them in-house, ceding some control over trial timing, data collection, and regulatory reporting. Ersodetug has received Orphan Drug Designation, Rare Pediatric Disease Designation, and Breakthrough Therapy Designation from the FDA, plus PRIME designation from the European Medicines Agency, positioning it for expedited review once pivotal data reads out. Competing hyperinsulinism programs are under development at Amylyx Pharmaceuticals, Hanmi Pharmaceuticals, and Zealand Pharma. As of September 15, 2025, Rezolute employed 77 full-time staff, most in research and development, reflecting its focus on clinical execution rather than commercial infrastructure.
Show full overview
Rezolute's near-term valuation hinges almost entirely on binary trial readouts rather than a diversified pipeline: topline sunRIZE data were anticipated in December 2025, and upLIFT results are expected in the second half of calendar 2026, with no other late-stage asset to offset a negative outcome on either study. The 10-K also flags reliance on external contract manufacturers for both raw materials and any future commercial-scale production, since Rezolute has no in-house commercial manufacturing experience. With $167.9 million in cash and marketable securities against a $403.9 million accumulated deficit, a delayed or failed readout would compress the runway management says covers at least 12 months from the filing date.
See also: Healthcare · Biotechnology
From Rezolute, Inc.'s most recent 10-K filing, extracted October 4, 2026.
Recent developments
updated 2026-10-13Recent Developments — Rezolute, Inc.
Latest news
- NEWS This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday — benzinga Oct 7, 2026 neutral
- NEWS Lake Street Maintains Buy on Rezolute, Raises Price Target to $12 — benzinga Oct 6, 2026 positive
- NEWS Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15 — benzinga Oct 6, 2026 positive
- NEWS This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday — benzinga Oct 6, 2026 positive
- NEWS Cantor Fitzgerald Upgrades Rezolute to Overweight — benzinga Oct 6, 2026 positive
Generated 2026-10-13T11:47:15Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelineersodetug lead clinical asset10-K Item 1: 'Our lead clinical asset, ersodetug, is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.87: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $4.53. Score 5.3/10, moderate confidence.
Take-profit target: $8.53 (+75.1% upside). Prior stop was $4.53. Stop-loss: $4.53.
Quality below floor (1.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (9 sells, 4.04% of cap).
Rezolute, Inc. trades at a P/E of N/A (forward -10.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover RZLT with a consensus score of 4.2/5. Average price target: $10.
What does Rezolute, Inc. do?Rezolute is a late-stage rare disease company focused on hypoglycemia caused by hyperinsulinism. Its lead clinical...
Rezolute is a late-stage rare disease company focused on hypoglycemia caused by hyperinsulinism. Its lead clinical asset, ersodetug, is an intravenously administered antibody being studied for multiple forms of hyperinsulinism. It has no commercial revenue disclosed in Item 1.